Vanda Pharmaceuticals Inc. VNDA R2KR3KPHARMA
Company Overview
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Why Investors Should Care
Revenue has grown at a 27.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Dec 2025 Revenue of $216.10M (+8.7% YoY); net profit $-220.47M.
- Trailing 12 Months Year-on-year growth — revenue -3.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.29% |
| 1 Year: | -3.90% |
Stock Price Performance
| 1 Year: | +22.59% |
| 6 Months: | -32.26% |
| 3 Months: | -11.36% |
| 1 Month: | +4.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.3% over 5 years.
CONS
- Trading 44.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VNDA Vanda Pharmaceuticals Inc. R2KR3KPHARMA | 5.34 | -1.15 | $322.87M | 0.00% | -43.97% | -77.81% | 27.29% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 43.59M | 47.35M | 49.13M | - | 47.71M | 59.06M | 59.48M | - | 58.00M | 62.21M | 60.31M | - | 62.67M | 67.90M | 70.09M | 60.19M | 64.39M | 65.32M | 62.50M | 46.06M | 38.81M | 47.46M | 50.47M | 47.65M | 50.04M | 52.59M | 56.26M | 57.22M | 51.72M | 50.53M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.52M | 2.74M | 2.95M | 3.83M | 3.16M | - |
| Gross Profit | 18.89M | 22.73M | 24.36M | 26.59M | 28.55M | 30.87M | 32.96M | 37.09M | 36.38M | 39.05M | 38.68M | 41.74M | 43.67M | 46.99M | 42.22M | 52.31M | 52.33M | 54.34M | 52.42M | 55.99M | 54.04M | 60.87M | - | - | - | - | - | - | - | - | - | - | - | - | 46.52M | 49.85M | 53.30M | 53.38M | 48.56M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.55M | 88.36M | 84.59M | 93.74M | 98.78M | - |
| Operating Income | -9.54M | -14.89M | -12.47M | -4.79M | -653.00K | -654.00K | -7.91M | -1.92M | -4.92M | -2.15M | 2.44M | 3.91M | 6.23M | 9.15M | -2.09M | 9.89M | 10.76M | 4.24M | -125.00K | 9.17M | 7.74M | 10.45M | 10.34M | 12.37M | 10.82M | -7.67M | 3.46M | 3.91M | 2.00M | -2.87M | -6.00M | -9.23M | -10.15M | -11.00M | -41.03M | -38.50M | -31.28M | -40.35M | -50.22M | -63.81M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -38.20M | -36.75M | -29.23M | -34.49M | -46.70M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.37M | -34.89M | -28.39M | -38.00M | -48.42M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.87M | -7.68M | -5.80M | 103.19M | 143.00K | - |
| Net Income | -9.46M | -14.80M | -12.36M | -4.62M | -430.00K | -604.00K | -7.64M | -1.53M | -4.55M | -1.84M | 3.07M | 4.61M | 7.17M | 10.36M | -612.00K | 11.53M | 100.42M | 4.22M | 486.00K | 8.71M | 5.95M | 8.19M | 8.65M | 9.65M | 7.77M | -6.43M | 2.57M | 3.27M | 3.25M | 1.52M | 137.00K | -4.15M | -4.52M | -5.32M | -29.49M | -27.21M | -22.59M | -141.19M | -48.57M | -62.51M |
| Diluted EPS | - | - | - | - | - | - | -0.17 | -0.03 | -0.10 | - | 0.06 | 0.09 | 0.13 | 0.19 | -0.01 | 0.21 | 1.84 | 0.08 | 0.01 | 0.16 | 0.11 | 0.15 | 0.15 | 0.17 | 0.14 | -0.11 | 0.05 | 0.06 | 0.06 | 0.03 | 0.00 | -0.07 | -0.08 | -0.09 | -0.50 | -0.46 | -0.38 | -2.39 | -0.82 | -1.04 |
| R&D Expense | 9.97M | - | 7.55M | 6.70M | 7.29M | - | 10.57M | 7.65M | 10.18M | - | 9.42M | 9.87M | 11.39M | - | 13.28M | 10.95M | 11.35M | - | 15.53M | 12.90M | 12.30M | - | 16.13M | 20.25M | 19.65M | 20.97M | 21.49M | 24.86M | 19.24M | 16.65M | 16.60M | 21.15M | 16.66M | 16.78M | 35.71M | 21.99M | 22.56M | - | 28.43M | 36.95M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.55M | 35.71M | 31.27M | 32.73M | 33.88M | 50.16M | 109.92M | 146.02M | 165.08M | 193.12M | 227.19M | 248.17M | 268.68M | 254.38M | 192.64M | 198.77M | 216.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.28M | 14.80M | 11.31M | 13.04M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 230.10M | 177.84M | 187.46M | 203.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 223.77M | 191.80M | 228.12M | 354.23M |
| Operating Income | -35.95M | 8.84M | -10.71M | -29.18M | -21.20M | 20.06M | -40.19M | -18.57M | -16.90M | 21.74M | 22.81M | 27.24M | 42.16M | 6.33M | -13.95M | -40.66M | -151.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.06M | -9.62M | -30.86M | -139.25M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.30M | 6.34M | -22.92M | -138.65M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.03M | 3.83M | -4.02M | 81.83M |
| Net Income | -35.86M | 7.19M | -9.80M | -28.62M | -21.05M | 20.19M | -39.87M | -18.01M | -15.57M | 25.21M | 115.55M | 23.34M | 33.15M | 6.28M | 2.51M | -18.90M | -220.47M |
| Diluted EPS | -1.33 | 0.25 | -0.35 | -1.01 | -0.69 | 0.55 | -0.94 | -0.41 | -0.35 | 0.48 | 2.11 | 0.42 | 0.58 | 0.11 | 0.04 | -0.33 | -3.74 |
| R&D Expense | 13.87M | 12.34M | 29.00M | 45.76M | 28.50M | 19.23M | 29.14M | 29.16M | 38.55M | 43.59M | 48.65M | 55.58M | 75.36M | 85.77M | 76.82M | 74.43M | 109.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 213.10M | 182.62M | 135.45M | 143.35M | 171.70M | 213.05M | 210.37M | 205.43M | 332.13M | 483.75M | 533.46M | - | 634.25M | 648.44M | 656.20M | 488.95M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 519.29M | 432.95M | 438.89M | 347.26M |
| Cash & Equivalents | 39.08M | 205.29M | 42.56M | 87.92M | 88.77M | 64.76M | 60.90M | 50.84M | 40.43M | 33.63M | 61.01M | 45.07M | 61.03M | - | 135.03M | 135.82M | 102.32M | 84.85M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.19M | 1.36M | 1.73M | 1.85M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.51M | 34.16M | 47.10M | 54.58M |
| Total Liabilities | - | - | 175.37M | 149.14M | 125.54M | 99.22M | 10.89M | 80.02M | 79.04M | 74.04M | 56.71M | 72.80M | 80.19M | - | 107.05M | 103.53M | 117.66M | 161.76M |
| Current Liabilities | - | - | 31.03M | 31.62M | 32.26M | 32.85M | 7.79M | 51.32M | 50.32M | 70.36M | 53.02M | 59.51M | 65.94M | - | 91.44M | 87.70M | 99.98M | 145.16M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.14M | 9.40M | 12.36M | 12.62M |
| Total Equity | 46.02M | 23.03M | 37.73M | 33.47M | 9.90M | 44.12M | 160.82M | 133.03M | 131.33M | 131.39M | 275.42M | 410.94M | 453.27M | - | 527.20M | 544.91M | 538.55M | 327.19M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.78M | 57.53M | 58.31M | 59.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 169.34M | -10.90M | -28.41M | -44.92M | -39.59M | - | - | - | -1.98M | 29.99M | 45.95M | 51.77M | - | 31.98M | 12.80M | -15.76M | -109.44M |
| Investing Cash Flow | -4.74M | -155.62M | 73.75M | 45.75M | -34.27M | - | - | - | -10.23M | -109.66M | -68.31M | -41.50M | - | 49.92M | -12.06M | -17.43M | 94.86M |
| Financing Cash Flow | 1.62M | 3.78M | 25.00K | 12.00K | 49.86M | - | - | - | 5.25M | 107.13M | 6.26M | 5.63M | - | 734.00K | 0 | -155.00K | -2.91M |
| Capital Expenditure | - | - | -275.00K | -2.02M | -176.00K | -769.00K | -2.53M | -1.41M | -1.66M | -368.00K | -1.02M | -1.79M | - | -679.00K | -383.00K | -490.00K | -998.00K |
| Free Cash Flow | - | - | -28.68M | -46.93M | -39.77M | - | - | - | -3.65M | 29.62M | 44.93M | 49.98M | - | 31.30M | 12.42M | -16.25M | -110.44M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 82.64M | 745.00K | -33.34M | -17.49M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 90.5% | 92.3% | 94.3% | 94.0% |
| Operating Margin % | -790.4% | 24.8% | -34.2% | -89.2% | -62.6% | 40.0% | -36.6% | -12.7% | -10.2% | 11.3% | 10.0% | 11.0% | 15.7% | 2.5% | -7.2% | -20.5% | -70.0% |
| Net Margin % | -788.5% | 20.1% | -31.3% | -87.4% | -62.1% | 40.2% | -36.3% | -12.3% | -9.4% | 13.1% | 50.9% | 9.4% | 12.3% | 2.5% | 1.3% | -9.5% | -102.0% |
| ROE % | -155.7% | 19.1% | -29.3% | -288.9% | -47.7% | 12.6% | -30.0% | -13.7% | -11.8% | 9.2% | 28.1% | 5.1% | - | 1.2% | 0.5% | -3.5% | -67.4% |
| ROCE % | - | 4.9% | -7.1% | -28.3% | -19.2% | 12.2% | -24.8% | -11.6% | -12.5% | 7.8% | 5.4% | 5.8% | - | 1.2% | -2.5% | -7.3% | -44.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.66% | 7.65M | $40.49M |
| 2 | State Street Corporation | 5.82% | 3.52M | $18.60M |
| 3 | AQR Capital Management, LLC | 5.78% | 3.50M | $18.50M |
| 4 | Renaissance Technologies, LLC | 5.69% | 3.44M | $18.20M |
| 5 | Vanguard Capital Management LLC | 4.17% | 2.52M | $13.35M |
| 6 | AIGH Capital Management LLC | 3.38% | 2.04M | $10.81M |
| 7 | Acadian Asset Management. LLC | 3.17% | 1.92M | $10.15M |
| 8 | Dimensional Fund Advisors LP | 2.86% | 1.73M | $9.14M |
| 9 | Millennium Management Llc | 2.65% | 1.60M | $8.48M |
| 10 | Geode Capital Management, LLC | 2.45% | 1.48M | $7.85M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VNDA
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxOd2xBcEF1cXppWXNRdW9rUUlSRUtMM0pzY2lkY2VGaFdzdzdadVZLb1NpTng0QWNkTENGSTYxOFFwdmdDV1F6dHJueDVEVWJ3dzU1TExEdUVnTENnZE1PLWg3X2JLbFVaRlBHNWlhTFNxSVU0Q2tNUnlaY1JZQ0RtTVYtTDFKRldFTm5YeX…
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOcHBnZUhEM3kzRkZoZzg5VmtEejlYSERRNE5HdVBFd0VhMXZ0V0hNZTdGaUFuYzk2Q1VBNWI1QkxBcjF3VW4tY2habUV1MDAyNG5Zdi1Ua3ctOXBBSV92RU85eUFaMzBLVUVuNy1pQ3ByY3B3RGMzQXQ5SS00NEt4bng2ckRyQTlXT0NkdD…
Four September conferences are planned for Vanda Pharmaceuticals. Two presentations may be accessed live. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPOW9LTWZMSGtpQm1pd29Wbmdza3IyV0VsdGZJQU1FejhyQUpVeDg3bWpUX1ZyN0o2REVlY3JWb1NOUzk0NU5nMjNxTEpZdGlLWkttSFpuRHpWckVlS3RHUFNaNjYyRm5KNXE5NnRUbXZ6NERMYnI3NDdkMlVXUXZ2WnRsZ2dfak1DTU1BbG…
$VNDA stock is up 11% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQMkszWlhqX0xoNkZhSVBrcmpzaVQyUWF5S1RtZy1DUEloMnFyVEVPeHJNemVRVzdFT2NkRFprVkwtSDV1ellXeHJaWWtoUWYtUmZvaGd3QVhienl2MGItZ1NwNF9hWUVzOEdrclZUOUtEalpDaUxQYV9oOTk5Z1lCZnlXUXBnRDRYeTBWUX…
VNDA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBEZ2ZJbTFuN1pxb0dCaWtVM3M0WFFuWVY1V1ZwcHoyVS13NWx2b1dwS2tMQk9rMjNKUi1RdVVpM1pWYVVDRWItMHp6Q2s3SUx0RjNjVHJJSVN1eS1QbVhLeDFaX3ZzSkxTUjhYNmVubHJ2a2hDdGh4RVln?oc=5" target="_blank">VND…
VNDA - Vanda Pharmaceuticals Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBnMUVhSXZ5R0wxZVhYVGdhelNiU0ktckJ1elE2R2pnR2NFa2xiUFRJM1BQS1hlbWRJUUR0UVNGeENiMDNDZUE?oc=5" target="_blank">VNDA - Vanda Pharmaceuticals Inc Stock Price and Quote</a> <f…
VNDA — Frequently Asked Questions
What is the current share price of Vanda Pharmaceuticals Inc. (VNDA)?
As of 2026-09-07 16:24 PDT, Vanda Pharmaceuticals Inc. (VNDA) trades at $5.34 on NasdaqGM. Its 52-week range is $4.32 to $9.56.
What is the market capitalisation of VNDA?
Vanda Pharmaceuticals Inc. (VNDA) has a market capitalisation of $322.87M on NasdaqGM.
What is the P/E ratio of VNDA?
VNDA trades at a trailing price-to-earnings (P/E) ratio of -1.15. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.07.
What is the return on equity (ROE) of VNDA?
VNDA has a return on equity (ROE) of -77.81%. Its return on capital employed (ROCE) is -43.97%.
Is VNDA a good stock to buy?
This page provides a data-driven analysis of Vanda Pharmaceuticals Inc. (VNDA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.